Ghrelin levels are suppressed and show a blunted response to oral glucose in women with polycystic ovary syndrome
Ghrelin levels are suppressed and show a blunted response to oral glucose in women with polycystic ovary syndrome
复制标题
DOI：
10.1530/eje-07-0683
复制
发表时间：
2008-04-01
影响因子：
5.8
通讯作者：
Wass, John A. H.
中科院分区：
文献类型：
--
作者：
Barber, Thomas M.;Casanueva, Felipe F.;Wass, John A. H.
目的：异常的生长素释放肽调节可能影响肥胖相关疾病的发展，包括多囊卵巢综合征（PCOS）。我们的目的是比较 PCOS 病例和对照之间的生长素释放肽调节。 设计：我们比较了 50 名 PCOS 病例和 28 名女性对照者的血清生长素释放肽（总）水平、空腹和口服后 30 分钟（75 g）葡萄糖负荷，其中包括 22 组体重指数 (BMI)/脂肪量匹配组。所有受试者均为英国/爱尔兰血统。方法：测量包括血清生长素释放肽（RIA 技术（LINCO Research，圣查尔斯密苏里州，美国））、脂肪量、血清睾酮、空腹血清胰岛素和血浆葡萄糖水平。胰岛素敏感性计算为胰岛素抵抗的稳态模型评估（HOMA2 IR）。结果：与BMI/脂肪量匹配的对照组（几何平均值（S.D）范围）相比，PCOS病例的空腹血清生长素释放肽水平显着降低，分别为1104 pg/ml（764-1595）和1756 pg/ml（1314-2347）； P=2.3X10(-4))。与BMI/脂肪量匹配的对照组相比，PCOS病例中口服葡萄糖负荷后的Ghrelin抑制显着减弱（几何平均Ghrelin抑制（S.D.范围）分别为160 pg/ml (88-289) vs 424 pg/ml (220-81.8)；P=2.0 X 10(-4)）。根据脂肪量和年龄进行调整的全组比较（50 例 PCOS 病例与 28 例对照）显示相似的结果。在PCOS病例中，空腹血清ghrelin与HOMA2 IR之间存在显着负相关（r(2) = -0.40，P = 5.7 X 10(-3)）。在调整 HOMA2 IR、脂肪量和年龄后，PCOS 病例和对照组的整个组之间的比较显示，空腹血清 ghrelin (P = 1.3X10(-3)) 和 ghrelin 抑制 (P = 1.8X10(-3)) 存在减弱但显着的差异。 结论：在患有 PCOS 的女性中，血清 ghrelin 水平受到抑制，与 HOMA2 IR 呈负相关，并且对口服药物的反应减弱葡萄糖。
Objective: Abnormal ghrelin regulation may influence the development of obesity-associated conditions including polycystic ovary syndrome (PCOS). Our aim was to compare ghrelin regulation between PCOS cases and controls.Design: We compared serum ghrelin (total) levels, fasting and 30-min post-oral (75 g) glucose load, between 50 PCOS cases and 28 female controls, including 22 body mass index (BMI)/fat mass-matched pairs. All subjects were of UK British/Irish origin.Methods: Measurements included serum ghrelin (RIA technique (LINCO Research, St Charles MO, USA)), fat mass, serum testosterone, fasting serum insulin and plasma glucose levels. Insulin sensitivity was calculated as the homeostasis model assessment of insulin resistance (HOMA2 IR).Results: Fasting serum ghrelin levels were significantly lower in PCOS cases versus BMI/fat mass-matched controls (geometric mean (S.D). range), 1104 pg/ml (764-1595) vs 1756 pg/ml (1314-2347) respectively; P=2.3X10(-4)). Ghrelin suppression following oral glucose load was significantly blunted in PCOS cases versus BMI/fat mass-matched controls (geometric mean ghrelin suppression (S.D. range), 160 pg/ml (88-289) vs 424 pg/ml (220-81.8) respectively; P=2.0 X 10(-4)). Whole-group comparisons (50 PCOS cases versus 28 controls) adjusted for fat mass and age revealed similar results. In PCOS cases, there was a significant negative correlation between fasting serum ghrelin and HOMA2 IR (r(2) = -0.40, P = 5.7 X 10(-3)). Following adjustment for HOMA2 IR, fat mass and age, comparisons between the whole groups of PCOS cases and controls revealed attenuated but significant differences in fasting serum ghrelin (P = 1.3X10(-3)) and ghrelin suppression (P = 1.8X10(-3)).Conclusions: In women with PCOS, serum ghrelin levels are suppressed, showing a negative relationship with HOMA2 IR and a blunted response to oral glucose.